37 citations
,
September 2017 in “Reumatología Clínica” Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
6 citations
,
December 2015 in “Medwave” Leflunomide can cause severe hair loss in some rheumatoid arthritis patients.
2 citations
,
January 2023 in “SAGE Open Medical Case Reports” Stopping leflunomide healed the woman's skin ulcers.
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
1 citations
,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
January 2010 in “Chinese Medical Journal of Metallurgical Industry” Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.
May 2026 in “Indian Dermatology Online Journal” Leflunomide can cause skin ulcers, and stopping it can lead to healing.
34 citations
,
November 2023 in “Applied Materials Today” Nanoemulsions can effectively treat skin cancer with fewer side effects.
19 citations
,
June 2011 in “British Journal of Dermatology” Severe digestive issues in DRESS need early endoscopy for better treatment.
10 citations
,
June 2019 in “Transplant infectious disease” The virus linked to a rare disease was found in a patient's blood and urine before skin symptoms appeared.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
1 citations
,
May 2026 in “Journal of Dermatological Treatment” JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
1 citations
,
June 2013 in “Annals of the Rheumatic Diseases” Methotrexate plus prednisolone had the fewest serious side effects.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
July 2025 in “Pediatric Transplantation” A rare skin infection in a 10-year-old kidney transplant patient was successfully managed by adjusting medication.
November 2024 in “Rheumatology Advances in Practice” Rheumatology clinics should always provide preconception counseling for women on DMARDs.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
13 citations
,
January 1999 in “Postgraduate Medicine” New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.